Investment Thesis
Corbus Pharmaceuticals faces critical operational challenges with only $2.8M revenue against -$24.3M operating losses and -$25.6M annual cash burn. At current burn rates, cash runway extends approximately 12 months, while deteriorating EPS (-60.3% YoY) and minimal revenue signal fundamental business failure or severe pipeline delays. The strong balance sheet provides temporary protection but cannot offset unsustainable core operations.
Strengths
- Zero long-term debt with Debt/Equity ratio of 0.00x eliminates leverage risk
- Strong liquidity position with Current Ratio of 7.92x enabling operational continuity
- Substantial equity base of $126.3M providing financial cushion against imminent insolvency
Risks
- Critically low revenue generation of $2.8M with no evidence of commercial product success
- Unsustainable annual cash burn of -$25.6M implying ~12-month cash runway at current trajectory
- Severe operating losses of -$24.3M on minimal revenue base with worsening diluted EPS (-60.3% YoY decline)
- Undefined gross profit structure (N/A reported) indicating either revenue volatility or production/supply constraints
Key Metrics to Watch
- Quarterly cash burn rate and revised cash runway estimates
- Sequential revenue trends and regulatory/commercialization milestones
- Operating expense trajectory and ability to reduce burn rate
- Clinical trial progress and pipeline advancement announcements
Financial Metrics
Revenue
2.8M
Net Income
-23.0M
EPS (Diluted)
$-1.23
Free Cash Flow
-25.6M
Total Assets
144.5M
Cash
25.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-881.5%
Net Margin
-833.1%
ROE
-18.2%
ROA
-15.9%
FCF Margin
-927.7%
Balance Sheet & Liquidity
Current Ratio
7.92x
Quick Ratio
7.92x
Debt/Equity
0.00x
Debt/Assets
12.6%
Interest Coverage
N/A
Long-term Debt
0.0
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T06:51:02.050420 |
Data as of: 2026-03-31 |
Powered by Claude AI